Atorvastatin: An effective lipid-modifying agent in familial hypercholesterolemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 8, 1997, Pages 1527-1531

  Marais, A David ^a   Firth, Jean C ^a   Bateman, Mary E ^a   Byrnes, Pam ^a   Martens, Candice ^b   Mountney, Jean ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Parke Davis Pharmaceuticals   (South Africa)

Author keywords

Atorvastatin; Familial hypercholesterolemia; HMG CoA reductase inhibitors

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL;

EID: 0030885273     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.8.1527     Document Type: Article

References (27)

1. Brown MS, Goldstein JL. A receptor mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
2. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Human Mutat. 1992;1:445-446.
3. Slack J. Risks of ischaemic heart disease in familial hyperlipoproteinemic states. Lancet. 1969;2:1380-1382.
4. Seftel HC, Baker SG, Sandler MP, Forman MB, Joffe BI, Mendelsohn D, Jenkins T, Mieny CJ. A host of hypercholesterolemic homozygotes in South Africa. Br Med J. 1980;281:633-636.
5. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease. Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis. 1992;2:113-156.
6. Summary of the Second Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
7. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988;319:24-32.
8. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
9. Parzer S, Mannholter S. A rapid method for the isolation of genomic DNA from citrated whole blood. Biochem J. 1991;273:229-231.
10. Graadt van Roggen JF, van der Westhuyzen DR, Marais AD, Gevers W, Coetzee GA. Low density lipoprotein receptor founder mutations in Afrikaner familial hypercholesterolemic patients: a comparison of two geographical areas. Ann Hum Genet. 1991;88:204-208.
11. Meiner V, Landsberger D, Berkman N, Reshef A, Segal P, Seftel HC, van der Westhuyzen DR, Coetzee GA, Leitersdorf E. A common Lithuanian mutation causing familial hypercholesterolemia in Ashkenazi Jews. Am J Hum Genet. 1991;49:443-449.
12. Henderson HE, Berger GMB, Marais AD. A new LDL receptor gene deletion mutation in the South African population. Hum Genet. 1988;80:371-374.
13. Kotze MJ, Langenhoven E, Peeters AV, Theart L, Oosthuizen CJJ. Detection of two point mutations causing familial binding defective apolipoprotein B100 by heteroduplex analysis. Mol Cell Probes. 1994 In press.
14. Mol MJTM, Erkelens DW, Gevers Leuven JA, Schouten JA, Stalenhoef AFH. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolemia. Lancet 1986;2:936-939.
15. Illingworth RI. HMG CoA reductase inhibitors. Curr Opin Lipidol. 1991;2:24-50.
16. Naoumova RP, Marais AD, Mountney J, Firth JC, Rendell NB, Taylor GW, Thompson GR. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis. 1996;119:203-213.
17. Hagemenas FC, Pappu AS, Illingworth DR. The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolemia. Eur J Clin Invest. 1990;20:150-157.
18. Kotze MJ, de Villiers WJS, Steyn K, Kriek JA, Marais AD, Langenhoven E, Herbert JS, Graadt van Roggen JF, van der Westhuyzen DR, Coetzee GA. Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler Thromb. 1993;13:1460-1468.
19. Jeenah M, September W, Graadt van Roggen F, de Villiers W, Seftel H, Marais D. Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 1993;98:51-58.
20. Illingworth DR, Vakar F, Mahley RW, Weisgraber KH. Hypocholesterolemic effects of lovastatin in familial defective apolipoprotein B-100. Lancet. 1992;339:598-600.
21. Austin MA. Genetics of low density lipoprotein subclasses. Curr Opin Lipidol 1993;4:125-132.
22. Yuan J, Tsai MY, Hegland J, Hunninghake DB. Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis. 1991;87:147-157.
23. Cheung MC, Austin MA, Moulin P, Wolf AC, Cryer D, Knopp RH. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis. 1993;102:107-119.
24. Yuan J, Tai MY, Hunninghake DB. Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis. 1994;110:1-10.
25. Hokanson JE, Austin MA, Zambon A, Brunzell JD. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb. 1993:13:427-434.
26. Beigel Y, Fuchs J, Snir M, Lurie Y, Green P, Djaldetti M. Lovastatin therapy in heterozygous familial hypercholesterolemic patients: effect on blood rheology and fibrinogen levels. J Intern Med. 1991;230:23-27.
27. Illingworth RI, Bacon S, Pappu AS, Sexton GJ. Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 1992;96:53-64.